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In a prospective cohort study of 74250 Swedish women and men, with 7.2 years of follow-up and 705 incident colorectal cancer
cases, long duration of aspirin use (420 years) was associated with a reduced risk of colorectal cancer (multivariate rate ratio: 0.65;
95% confidence interval: 0.45–0.94). Aspirin use for a shorter period was not associated with risk.
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More than 15 case–control and cohort studies have suggested that
aspirin use may lower the risk of colorectal cancer (Bosetti et al,
2002). Furthermore, randomised trials have demonstrated that
regular use of aspirin reduces the risk of recurrent adenoma within
1–3 years in patients with prior colorectal adenoma or cancer
(Baron et al, 2003; Benamouzig et al, 2003; Sandler et al, 2003).
However, two other randomised trials that evaluated the effect
of aspirin on colorectal cancer did not show a reduction in risk
after 5 or 10 years (Gann et al, 1993; Cook et al, 2005). Therefore,
it remains unclear whether aspirin use for a longer time would
lower the risk of colorectal cancer. Results from a recent large
prospective cohort of US women showed that a significant benefit
of aspirin was not evident until more than 10 years of use and with
six or more 325-mg aspirin tablets per week (Chan et al, 2005).
The purpose of this study was to examine prospectively
frequency and duration of aspirin use in relation to colorectal
cancer incidence in a population-based cohort study of 74250
Swedish women and men.
MATERIALS AND METHODS
Study population
Two population-based prospective cohort studies of women and
men in central Sweden provided data for these analyses: the
Swedish Mammography Cohort and the Cohort of Swedish
Men. The Swedish Mammography Cohort was established between
1987 and 1990 when all women born between 1914 and 1948
and residing in Va ¨stmanland and Uppsala counties received a
mailed questionnaire on diet, weight, height, and education. In the
autumn of 1997, all 56030 living participants obtained a new
questionnaire that was expanded to include about 350 items
concerning diet and other lifestyle factors, medication use
(including aspirin), medical history, etc; 39227 women completed
this questionnaire. The Cohort of Swedish Men began in the
autumn of 1997 when 48850 men born between 1918 and 1952
and residing in Va ¨stmanland and O ¨rebro counties responded
to a mailed questionnaire that was identical to the Swedish
Mammography Cohort questionnaire from 1997. Both studies were
approved by the ethics committees at the Karolinska Institutet
(Stockholm, Sweden) and the Uppsala University Hospital
(Uppsala, Sweden).
For these analyses, we excluded those who did not complete the
1997 questionnaire and those who did not provide information
on aspirin use. We also excluded those with incorrect or missing
national registration number and those with a previous diagnosis
of cancer (except nonmelanoma skin cancer). This left 74250
participants (32076 women and 42174 men), aged 45–83 years in
1997, eligible for analyses.
Assessment of exposures
In 1997, participants completed a questionnaire on demographic
characteristics, weight, height, and medical, smoking, dietary,
and physical activity history. Participants were asked to report
whether they used aspirin or aspirin-containing medicines and, if
so, how many aspirin tablets per week and for how many years. In
Sweden, the majority of aspirin-containing medicines contain
500mg aspirin. Data on non-aspirin nonsteroidal anti-inflamma-
tory drugs (NSAIDs) were not available.
Case ascertainment and follow-up
Incident cases of colorectal adenocarcinomas were identified
by computerised linkage to the national and regional Swedish
cancer registries, both of which provide nearly 100% case
ascertainment in Sweden (Mattsson and Wallgren, 1984). By
linkage to the Swedish Death and Population registers at Statistics
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Statistical analysis
Person-time of follow-up was counted for each participant from 1
January 1998 until the date of colorectal cancer diagnosis, death,
migration, or 30 June 2005, whichever came first. We used Cox
proportional hazards modeling (Cox, 1972) to calculate rate ratios
(RRs) with 95% confidence intervals (CIs). Age in months and
sex were adjusted for as stratification variables in the model.
In multivariate analyses, we further adjusted for education (less
than high school, high school graduate, or more than high
school), family history of colorectal cancer (yes/no), body mass
index (o23.0, 23.0–24.9, 25.0–29.9, or X30kgm
 2), leisure-time
physical activity (h/week; four categories), history of diabetes
(yes/no), and smoking (never, past, or current smoker). Tests of
linear trends across categories of aspirin use were conducted by
assigning the median value of aspirin use for categories and
treating these as a single continuous variable. All analyses were
conducted with SAS statistical software, version 9.1 (SAS Institute
Inc., Cary, NC, USA). All reported P-values are based on two-sided
statistical tests.
RESULTS
At baseline, about 51% of women and 37% of men reported aspirin
use. Aspirin users did not differ substantially from nonusers with
respect to age, education, family history of colorectal cancer, body
mass index, physical activity, diabetes, or smoking status (Table 1).
Among the 74250 women and men, we ascertained 705 incident
cases of colorectal adenocarcinoma (261 women and 444 men)
during a mean follow-up of 7.2 years, from 1998 through June
2005. Compared with nonusers, women and men who reported
use of more than six aspirin tablets per week had a statistically
significant 23% lower risk of colorectal cancer after adjusting for
age, sex, and other known and potential risk factors (Table 2). The
association was similar for colon and rectal cancers, but appeared
to be stronger for distal (multivariate RR, 0.53; 95% CI, 0.30–0.93)
than proximal colon cancer (multivariate RR, 0.82; 95% CI,
0.52–1.30). When we examined duration of aspirin use, significant
risk reduction was not observed until more than 20 years of
use (Table 2). Compared with nonuse, the multivariate RRs of
colorectal cancer for more than 20 years of aspirin use were 0.65
(95% CI, 0.45–0.94) in women and men combined, 0.57 (95% CI,
0.30–1.10) in women, and 0.70 (95% CI, 0.45–1.09) in men.
Further adjustment for postmenopausal hormone use among
women did not change the results materially (multivariate RR,
0.58; 95% CI, 0.30–1.11). The inverse association with long-term
aspirin use (420 years) seemed to be stronger for rectal cancer
than for colon cancer (Table 2). In women and men combined, the
association between long-term aspirin use and risk of colorectal
cancer remained after additional adjustment for intakes of alcohol,
red meat, calcium, and folate (all in quintiles) and multivitamin
supplement use (multivariate RR, 0.62; 95% CI, 0.42–0.90), and
after excluding the first 2 years of follow-up (multivariate RR, 0.65;
95% CI, 0.43–0.98).
DISCUSSION
In this population-based prospective study of Swedish women and
men, long-term (420 years) aspirin use was associated with a
statistically significant 35% reduction in risk of colorectal cancer.
Table 1 Baseline characteristics of the study population by sex and
aspirin use
a
Women Men
Characteristic
No aspirin
use
Aspirin
use
No aspirin
use
Aspirin
use
Participants (n) 15721 16355 26394 15780
Age, mean (years) 61.2 61.6 59.5 60.8
Postsecondary education (%) 18.0 21.1 16.4 17.5
Family history of colorectal
cancer (%)
7.3 8.2 6.8 7.3
Body mass index, mean
(kg/m
2)
25.0 25.1 25.7 26.0
Leisure-time physical activity
(h/week)
2.4 2.3 2.6 2.5
History of diabetes (%) 3.5 3.7 5.8 6.5
Current smoker (%) 23.3 23.6 24.5 29.5
aAll values (except age) are standardised to the age distribution of the study
population at baseline.
Table 2 RRs of colorectal cancer by dose and duration of aspirin use in a cohort of 74250 Swedish women and men, 1998–2005
Colorectal cancer Colon cancer Rectal cancer
Aspirin
No. of
cases
a
Person-years
of follow-up
Age- and sex-adjusted
RR (95% CI)
Multivariate
RR (95% CI)
b No. of cases
a
Multivariate
RR (95% CI)
b No. of cases
a
Multivariate
RR (95% CI)
b
Nonuse
c 417 304321 1.00 (reference) 1.00 (reference) 271 1.00 (reference) 149 1.00 (reference)
Use 288 230610 0.89 (0.76–1.03) 0.87 (0.75–1.01) 185 0.84 (0.69–1.02) 104 0.92 (0.72–1.19)
No. of tablets/week
1 45 42545 0.85 (0.62–1.16) 0.83 (0.61–1.14) 26 0.73 (0.48–1.09) 20 1.07 (0.67–1.72)
2–6 65 52524 0.91 (0.70–1.18) 0.88 (0.68–1.16) 38 0.77 (0.55–1.09) 27 1.09 (0.72–1.65)
46 70 44954 0.80 (0.62–1.04) 0.77 (0.59–0.99) 41 0.75 (0.55–1.03) 24 0.79 (0.51–1.22)
P-value for trend 0.09 0.04 0.05 0.37
Years of aspirin use
1–10 52 81165 0.98 (0.80–1.19) 0.96 (0.78–1.17) 78 0.88 (0.68–1.13) 50 1.09 (0.79–1.52)
11–20 27 24901 0.89 (0.60–1.31) 0.87 (0.59–1.29) 19 0.93 (0.58–1.49) 8 0.73 (0.36–1.51)
420 31 35481 0.66 (0.46–0.96) 0.65 (0.45–0.94) 23 0.76 (0.49–1.16) 9 0.52 (0.26–1.02)
P-value for trend 0.03 0.02 0.20 0.04
CI¼confidence interval; RR¼rate ratio;
aThe number of cases may not sum up to the total number of cases owing to missing information on number of tablets and years of
aspirin use. Four cases that were diagnosed with both colon and rectal cancer were included in analysis of both cancer sites.
bMultivariate RRs were adjusted for baseline age, sex,
education, family history of colorectal cancer, body mass index, leisure-time physical activity, history of diabetes, and smoking.
cReference group for all comparisons.
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potential colorectal cancer risk factors.
Three randomised trials have shown that short-term regular
aspirin use reduces the risk of recurrent adenoma in patients with
previous polyps or colorectal cancer (Baron et al, 2003;
Benamouzig et al, 2003; Sandler et al, 2003). However, findings
from the Women’s Health Study, a randomised controlled trial
including nearly 40000 women, did not show a reduction in
colorectal cancer risk after 10 years of treatment with low-dose
aspirin (100mg on each other day) (Cook et al, 2005). Another
randomised trial, involving about 22000 US male physicians, that
examined alternate-day use of 325mg of aspirin found no
association with the incidence of colorectal cancer during 5 years
of randomised treatment and follow-up (Gann et al, 1993). It is
possible, however, that the 10- and 5-year intervention periods in
these two trials (Gann et al, 1993; Cook et al, 2005) may have been
too short to produce clear effects. Additionally, with regard to the
Women’s Health Study, the dose may have been too low. In our
prospective study, a statistically significant reduction in colorectal
cancer incidence was not observed until more than 20 years of
aspirin use. Our findings are broadly consistent with those of the
Nurses’ Health Study, suggesting that a benefit of aspirin against
colorectal cancer may require long-term (410 years) use (Chan
et al, 2005). This same study also suggested that the effect of
aspirin use on colorectal cancer risk is dose dependent; the lowest
dose associated with a statistically significant reduction in risk was
6–14 aspirin tablets (325mg) per week (Chan et al, 2005). Recent
findings from the Women’s Health Initiative Observational Study
(Allison et al, 2006) showed no statistically significant association
between duration of aspirin use and colorectal cancer risk; the
relative risks associated with 10.1–20 years and 420 years
of aspirin use were 0.58 (95% CI, 0.24–1.37) and 0.77 (95% CI,
0.40–1.50), respectively, compared with nonuse. The absence of
a statistically significant association in the Women’s Health
Initiative Observational Study may be due to the small number
of cases reporting long-term aspirin use (n¼7 cases for 10.1–20
years and n¼12 cases for 420 years of use).
The strengths of our study include its prospective and
population-based design, the completeness of follow-up of
participants through linkage to population-based registers, in-
formation on multiple potential confounders, and data on
frequency and duration of aspirin use. The prospective design
eliminates recall bias and the virtually complete follow-up
minimises the possibility that our findings have been affected by
differential follow-up of exposed compared to unexposed indivi-
duals. Our study is limited by the lack of information on non-
aspirin NSAID use. Furthermore, we had limited statistical power
to examine the combined effect of frequency and duration of
aspirin use on risk of colorectal cancer. Some misclassification
of exposure to aspirin is likely to be present in our study.
Nondifferential misclassification would most likely result in
attenuation of the true relationship between aspirin use and
colorectal cancer and therefore is unlikely to explain our findings.
Although we adjusted for a wide range of potential confounders,
we cannot exclude the possibility that the observed association is
attributable to residual or unmeasured confounding.
In summary, our results suggest that long duration of aspirin
use may lower the risk of colorectal cancer. The association
between long duration of aspirin use and colorectal cancer risk
warrants further study.
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